Agennix Restructures, Cuts Staff in Wake of Talactoferrin Bomb
Agennix AG is cutting more than half of its work force and shutting down a small drug development facility in Houston, in the wake of the recent failure of its lead drug talactoferrin in a Phase III trial in non-small-cell lung carcinoma (NSCLC).
The Heidelberg, Germany-based firm said Friday morning it is letting go 37 staffers, across all areas, and is retaining 30 at its two remaining locations, in Planegg, near Munich, and in Princeton, N.J.
(Although formally registered in Heidelberg, the company does not maintain operations there.)
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter